22 Jul 2022
Digital Therapy Study Demonstrates Improved Outcomes for Post-Stroke Patients
Constant Therapy is a digital therapeutics company whose mobile program delivers personalized exercises that rebuild cognitive and speech function for individuals recovering from stroke or traumatic brain injury or living with aphasia, dementia, and other neurological conditions. The study analyzed data from Constant Therapy’s program and demonstrated that increased dosage frequency is associated with better therapy outcomes for individuals with post-stroke speech, language, and/or cognitive disorders.
Why it’s Notable:
- This study was conducted with data from over 2200 post-stroke patients which is a large real-world data set for a rehabilitation study, as many studies in the field typically include a single participant or fewer than 50 participants.
- This study demonstrates that there is an optimal amount of usage frequency associated with improved outcomes, with four days of practice per week being the optimal dosage. The clarity of this outcome may assist physicians when it comes to prescribing the digital therapy to patients and encouraging patient adherence.
Industry Implications:
- Self-directed digital therapy that a patient can undertake at home can help to alleviate the barriers to accessing the optimal level of care required of patients with brain injuries or cognitive disorders, such as provider shortages, coverage caps, geographic isolation, and lack of transportation.
- There are numerous digital therapeutics companies that have developed speech and cognitive digital biomarkers for the assessment or diagnosis of neuro-cognitive disorders that arise post-stroke or in neurological conditions like Alzheimer’s disease. Altoida (trial) and Winterlight (study) have completed clinical trials for vocal biomarkers in cognitive impairment and Mindmaze MindMotion GO has been studied in a clinical trial for motor-rehabilitation post-stroke.